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Background: European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) antimicrobial resistance
(AMR) data are used to inform gonorrhoea treatment guidelines; therefore the data need to be robust and
representative. We assessed the extent to which Euro-GASP reflects national measures of the AMR situation for
Neisseria gonorrhoeae across the European Union/European Economic Area (EU/EEA).
Methods: We compared data from Euro-GASP with published national gonococcal AMR data from 15 countries for
azithromycin, cefixime and ciprofloxacin for the period 2009 to 2013 and performed Poisson regression to identify
differences (p < 0.05) between the proportions of resistant isolates. The 2014 Euro-GASP AMR data for each country
(n = 19) were weighted to account for differences in the distribution of patient characteristics between Euro-GASP
and EU/EEA epidemiological gonorrhoea surveillance data. Data were compared to determine whether estimates of
resistance levels differed with regards to the 5% threshold used to assess the clinical utility of first-line gonorrhoea
treatments. We assessed the quality of decentralised testing by comparing AMR data for isolates tested both
centrally and in the participating laboratories, and by evaluating external quality assessment (EQA) performance.
Results: There was no significant difference for azithromycin, cefixime and ciprofloxacin resistance when Euro-GASP
country data were compared with data from national reports. Weighting slightly altered the Euro-GASP AMR
estimates (by between − 4.7 and 4.7% from the unweighted estimates). Weighting resulted in greater changes in
estimates of resistance to azithromycin (from − 9.5 to 2.7%) and ciprofloxacin (from − 14.8 to 17.9%) in countries
with low isolate numbers and low completeness of reporting (n = 3). Weighting caused AMR levels to fall below or
above the 5% threshold for cefixime or azithromycin, respectively in only two countries. Susceptibility category data
submitted from the decentralised Euro-GASP laboratories were concordant with the Euro-GASP data (> 90%). EQA
performance was also good; < 5% of the minimum inhibitory concentration (MIC) results differed by > 4-fold from
the modal MIC of the EQA isolate.
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Conclusions: The overall prevalence of AMR reported by Euro-GASP reflects closely the AMR situation for N.
gonorrhoeae in the EU/EEA. Euro-GASP data can be used to provide robust AMR estimates to inform the European
guideline for the management of gonorrhoea.
Keywords: Gonorrhoea, Treatment, Antimicrobial resistance, Surveillance, European gonococcal antimicrobial
surveillance programme (euro-GASP), Europe, European Union (EU), European Economic Area (EEA),
RepresentativenessBackground
Empirical treatment of patients with confirmed or sus-
pected gonorrhoea can reduce the duration of infection,
prevent further onward transmission and alleviate the
associated morbidity of gonorrhoea. As empirical ther-
apy is administered in the absence of an antimicrobial
susceptibility profile for the infecting isolate, the World
Health Organization (WHO) recommends that the se-
lected gonorrhoea treatment should have ≥95% probabil-
ity of being effective i.e. 5% or fewer of gonococcal
isolates are likely to be resistant to the antimicrobial
used for first-line empirical treatment [1]. To ensure ef-
fective empirical therapy, surveillance of antimicrobial
susceptibility in Neisseria gonorrhoeae, which informs re-
visions of gonorrhoea treatment guidelines, should be
robust, reliable and quality-assured.
The antimicrobial susceptibility of the gonococcal
population in the European Union/European Economic
Area (EU/EEA) is monitored by the sentinel European
Gonococcal Antimicrobial Surveillance Programme
(Euro-GASP), which was initiated in 2004 [2] and has
been funded, co-ordinated and expanded by the Euro-
pean Centre for Disease Prevention and Control (ECDC)
since 2009. Euro-GASP data have twice informed
changes to the first-line therapy recommended in the
European guideline on the diagnosis and treatment of
gonorrhoea; firstly by reporting the detection of high
levels of ciprofloxacin resistance in the mid-2000s [3]
and secondly by elucidating emerging resistance to cefix-
ime in 2009/10 [4]. Originally, Euro-GASP used only
centralised antimicrobial susceptibility testing, where
100–200 isolates from participating countries were sent
to a central reference laboratory for testing [5]. However,
since 2010, a more sustainable approach which includes
decentralised testing, has been utilised [6]. Euro-GASP
laboratories, usually one per country that also frequently
perform their own national or regional (sub-national)
gonococcal antimicrobial susceptibility surveillance, have
been invited to participate in decentralised testing by
submitting their own gonococcal antimicrobial suscepti-
bility data. It is important that this shift from a centra-
lised to decentralised testing strategy has a minimal
impact on the longitudinal data. Quality criteria havetherefore been agreed for countries to participate in
decentralised testing using their own methods to test an
agreed core antimicrobial panel: (i) a high concordance
between the laboratories’ own antimicrobial susceptibil-
ity testing data and susceptibility data generated by
Euro-GASP centralised susceptibility testing is required,
and (ii) decentralised testing laboratories need to per-
form consistently well in the Euro-GASP external quality
assessment (EQA) programme [7].
The provision of appropriate clinical, epidemiological and
behavioural data for gonorrhoea patients linked to the anti-
microbial susceptibilities of the collected gonococcal iso-
lates is an essential component of Euro-GASP. Risk factor
analysis can subsequently identify patient characteristics
which are associated with infection with antimicrobial-
resistant gonococcal isolates [8]. The ECDC additionally
performs annual epidemiological surveillance for gonor-
rhoea infection [9], so patient data from the Euro-GASP
can be compared with surveillance data enabling the repre-
sentativeness of Euro-GASP to be investigated. Evaluation
of the representativeness and validity of the antimicrobial
susceptibility and epidemiologic data is essential to appro-
priately inform treatment guidelines.
The aim of this study was to evaluate the extent to
which Euro-GASP data derived from a limited number
of isolates per country and from both centralised and
decentralised testing, reflect the antimicrobial resistance
situation for N. gonorrhoeae as portrayed by data from
routine national antimicrobial susceptibility surveillance
systems and other directed antimicrobial susceptibility
studies in the EU/EEA. Data from Euro-GASP were
compared with data from other national antimicrobial
susceptibility surveillance and survey sources in order to
assess the validity of Euro-GASP data as a proxy for esti-
mates based on larger national data sets. In addition, the
representativeness of Euro-GASP data was assessed by
applying weighting to Euro-GASP data to account for
differences in the distribution of patient characteristics
between the Euro-GASP patient data and the European
epidemiological gonorrhoea surveillance data. In
addition, we assessed the performance in the Euro-
GASP EQA of countries moving from centralised to
decentralised testing.
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Comparison of Euro-GASP and national or regional
gonococcal antimicrobial susceptibility data, 2009 to
2013
Data sources
During 2009 to 2013, 22 countries participated in Euro-
GASP: Austria, Belgium, Cyprus (since 2010), Denmark,
France, Germany, Greece, Hungary (since 2010), Iceland
(since 2013), Ireland (since 2010), Italy, Latvia, Malta,
the Netherlands, Norway, Portugal, Romania (2010–
2011), Slovakia, Slovenia, Spain, Sweden and the United
Kingdom. A PubMed search was performed to identify
annual national or sub-national data from 2009 to 2013,
produced from countries with laboratories participating
in Euro-GASP. Keywords were (‘<country name>’) AND
(‘gonorrhoea OR gonorrhoeae’). Additionally, a Google
search using the identical keywords was performed. If no
data were identified, an email was sent to the responsible
Euro-GASP microbiologist in the specific country to en-
quire whether any published national or regional data
were available.
These searches resulted in national datasets (see Add-
itional file 1) derived from: (i) Euro-GASP laboratories
which were also responsible for the production of na-
tional or sub-national gonococcal antimicrobial suscepti-
bility data: Austria, Belgium, Denmark, Greece, Italy,
Malta, Norway, Slovakia, Slovenia, Sweden and the
United Kingdom (only England and Wales included in
this paper), and (ii) Euro-GASP laboratories plus add-
itional laboratories in the same country (The
Netherlands, France) or solely non-Euro-GASP labora-
tories (Hungary and Germany). No published national
or sub-national data were available for comparison from
Cyprus, Iceland, Ireland, Latvia, Portugal, Romania and
Spain.
Data on the countries participating in decentralised
Euro-GASP, including methods for susceptibility testing,
can be found in Additional file 1. In the centralised test-
ing, Etest was performed for cefixime and ceftriaxone, and
Etest or an agar dilution breakpoint method for azithro-
mycin, ciprofloxacin, and spectinomycin. Etest or a full
agar dilution series was performed for gentamicin, and β-
lactamase production was identified using nitrocefin. The
Euro-GASP results were reported to ECDC through The
European Surveillance System (TESSy), along with associ-
ated pseudo-anonymised patient data (6).
In the present study, the total number of tested
isolates, the number of resistant isolates and the per-
centage of resistant isolates were recorded for each
year for azithromycin, cefixime, and ciprofloxacin
from the Euro-GASP data and the national/sub-na-
tional data where available. Ceftriaxone (low num-
bers of resistant isolates), β-lactamase production
(does not detect chromosomally-mediated penicillinresistance) and gentamicin (no resistance breakpoints
defined) were not included.
For the analysis of weighted patient characteristics,
epidemiological surveillance data were extracted from
the TESSy database. These data are reported annually
from EU/EEA Member States’ national surveillance sys-
tems. Only data from countries which also reported data
in Euro-GASP were included in the dataset.
Statistical analysis
Comparison of Euro-GASP and national data, 2009
to 2013 The incidence rate defines the proportion of re-
sistant isolates over the total number of isolates within a
year. To assess statistically significant differences be-
tween the incidence rates from Euro-GASP and the na-
tional dataset, mixed-effect poisson regression analyses
were used. For the poisson model, the dependent vari-
able was the number of resistant isolates within 1 year,
and the exposure command was the total number of iso-
lates (incidence rate) within that year. The independent
variable was the variable “system”, a binary variable for
the source of the isolate data (Euro-GASP vs national).
This allowed us to calculate whether the association be-
tween the two incidence rates was statistically signifi-
cant. We included time as a random variable as the
national and Euro-GASP datasets within 1 year are most
likely more strongly correlated with each other than with
other years.
To assess statistically significant differences at the EU/
EEA level, the variable country was included as a ran-
dom effect. A further analysis was performed at the EU/
EEA level to determine whether the source of data at na-
tional level affected the primary analysis. The source of
comparison data was defined as: (1) all data from the
Euro-GASP laboratory and (2) Euro-GASP laboratory
responsible for some or none of the Euro-GASP data.
Country data with too few positive tests were excluded
from all analyses (azithromycin and cefixime data from
Hungary, and cefixime data from Germany).
Results were expressed as incidence rate ratios (IRR)
with 95% confidence intervals (CI). The IRR provides a
relative measure to assess the strength of association
between the proportion of resistant isolates in the Euro-
GASP versus national data. If the IRR is < 1.0, the na-
tional/regional data were composed of fewer resistant
isolates than the Euro-GASP data. If the IRR is > 1.0, the
national data were composed of more resistant isolates
than the Euro-GASP data. If the IRR is 1.0, there was no
difference between the national/regional data and the
Euro-GASP data. No statistical significant differences be-
tween the two datasets (p > 0.05) suggests that the pro-
portion of resistant isolates as reported through Euro-
GASP reflect the national resistance levels.
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GASP resistance data were weighted according to the
distribution of specific patient characteristics as reported
through the national epidemiological surveillance system
and compared to the unweighted resistance levels to de-
termine whether estimates of resistance levels differed
with regards to the 5% threshold used to assess the clin-
ical utility of first-line gonorrhoea treatments.
For 19 countries (Figs. 1, 2 and 3), weights were esti-
mated, as previously described [10], to account for dif-
ferences in age (≤25 years versus > 25 years), gender and
sexual orientation (heterosexual versus men who have
sex with men (MSM) between the Euro-GASP data and
epidemiological surveillance data reported in 2014. All
data were extracted from TESSy. For those countries
which did not report the required patient data, no
weighting was calculated. The weighted and unweighted
resistance levels were then plotted for each country and
data were compared to determine whether resistance
levels shifted above or below the 5% threshold.
Quality assurance of decentralised antimicrobial
susceptibility testing In the first year of introduction of
decentralised testing (2010), applications were receivedFig. 1 Percentage of azithromycin resistant isolates in Euro-GASP 2014 and
(< 25 years and≥ 25 years)from the Euro-GASP laboratories in Belgium, Denmark,
France, Italy, the Netherlands, Portugal, Spain, Sweden
and the United Kingdom. The Euro-GASP laboratory in
Greece joined decentralised testing in 2011. A further
seven countries applied for decentralised testing until
2013: Austria, Cyprus, Iceland, Ireland, Malta, Norway
and Slovenia. Parameters to further assure the quality of
decentralised testing as well as data validity were
investigated.Comparison of antimicrobial susceptibility data
Available antimicrobial susceptibility data since 2006
from the laboratories’ own gonococcal antimicrobial sus-
ceptibility testing were matched per isolate to the cen-
tralised Euro-GASP data. In addition to β-lactamase,
azithromycin, ciprofloxacin and ceftriaxone data which
were available from 2006 in Euro-GASP, spectinomycin
data were available from 2008, and cefixime and genta-
micin data from 2009. Laboratories used either Etests or
agar dilution to determine the minimum inhibitory con-
centration (MIC) of each antimicrobial and inferred sus-
ceptibility categories, i.e. susceptibility, intermediate
susceptibility or resistance (see Additional file 1).estimates weighted for sexual orientation, gender and age group
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ies was calculated for azithromycin, spectinomycin, and
ciprofloxacin. If countries supplied MIC data with the
susceptibility category data then the percentage concord-
ance was calculated using EUCAST breakpoints [11]
other than for ciprofloxacin pre-2013 (resistance MIC >
0.5 mg/L). For cefixime, ceftriaxone and gentamicin
where full MICs were available, the concordance was
calculated as the number of isolates within two doubling
dilutions of the MICs. Positive and negative β-lactamase
results were compared and a percentage concordance
established. The acceptance rate for participation in
decentralised testing, agreed by the Euro-GASP network,
was that ≤5% of MIC results should differ by more than
two MIC doubling dilutions and there should be ≥90%
concordance for susceptibility categories and the β-
lactamase results.
Comparison of EQA data
All available Euro-GASP EQA MIC data were assessed
for each participating country up until the acceptance
for performance of decentralised testing. Concordance
was established by calculating the number of isolates
that were within 4-fold (two doubling dilutions) of the
modal MICs for the EQA isolates. To fulfil the decentra-
lised quality criteria, laboratories were required to have
≤5% of MIC results that differed by more than 4-fold
from the modal MIC of the EQA isolate.
Results
Comparison of Euro-GASP and national or sub-national
data, 2009 to 2013
A total of 39,889 isolates (including both Euro-GASP
and national/sub-national data) from 15 countries tested
over the period 2009 to 2013 were compared for suscep-
tibility to ciprofloxacin. This comparison of the pooled
Euro-GASP data with the pooled national/sub-national
antimicrobial susceptibility data for ciprofloxacin re-
vealed a high level of concordance overall (p = 0.691)
(Table 1), with only data from Germany (and only from
2011) provided by a non-Euro-GASP laboratory, display-
ing significantly more ciprofloxacin resistant isolates (by
50%) in the national/regional data compared with the
Euro-GASP data (IRR 1.5, CI 1.06–1.97, p = 0.018)
(Table 1). The comparison for azithromycin included 26,
267 isolates from 10 countries. The concordance was
also relatively high overall for azithromycin, with no sig-
nificant differences between the two datasets for the ma-
jority of countries (7/10 countries) and overall between
the national/sub-national data compared with the Euro-
GASP data (p = 0.269) (Table 1). The country with the
least amount of azithromycin resistant isolates compared
to the Euro-GASP dataset was Austria with 86% less re-
sistant isolates (IRR 0.14, CI 0.085–0.224, p < 0.0001)The Netherlands however, had more than double the
number of resistant isolates compared to the Euro-
GASP dataset (IRR 2.2, CI 1.32–3.76, p = 0.003) (Table
1). The cefixime analysis included 26,282 isolates from
10 countries. Concordance was lowest for cefixime sus-
ceptibility data, with no significant differences between
the two datasets for half of the countries (5/10 coun-
tries). There was no significant difference between the
national/regional data isolates and the overall Euro-
GASP data for cefixime (p = 0.102) (Table 1). Adjusting
for the source of comparison data in the model did not
affect the findings for any of the antimicrobials.
Weighted patient characteristics, 2014
For most countries (84.2%, 16/19) where comparative
epidemiological surveillance data were available, weight-
ing only slightly altered the estimates of overall anti-
microbial resistance (from − 4.7 to 4.7% difference)
(Figs. 1, 2 and 3). Larger differences were observed for
azithromycin (from − 9.5 to 2.7%) (Fig. 1) and ciproflox-
acin (from − 14.8 to 17.9%) (Fig. 3) for three countries
with low isolate numbers and low completeness of
reporting (Estonia and Iceland for ciprofloxacin and
Portugal for azithromycin) [12, 13]. Critically, most
(98.5%, 129/131) of the weighting did not cause esti-
mated resistance levels to shift over or below the 5%
threshold, which is used to assess the continued clinical
utility of first-line antimicrobials for gonorrhoea empir-
ical treatment. The exceptions were cefixime and azi-
thromycin resistance in Greece and Denmark,
respectively. For Greece, cefixime resistance changed
from 5.0 to 3.8% for the sexual orientation-weighted es-
timates, to 4.6% for gender and to 3.4% for age group
(Fig. 2). For Denmark, azithromycin resistance changed
from 3.7 to 6.4% for the sexual orientation-weighted es-
timates (Fig. 1). Sexual orientation data was not available
in either one of or both the Euro-GASP or the epi-
demiological surveillance datasets from Belgium, Cyprus,
France, Hungary, Iceland, Norway, Poland and Sweden,
and no age data were available from Poland in the epi-
demiological surveillance dataset.
Comparison of decentralised and centralised
susceptibility testing data
In total, 17 countries requested to participate in decen-
tralised testing from 2010 to 2013 (Table 2).
Susceptibility category concordance
For all examined years, ≥90% concordance of the suscep-
tibility categories was achieved for β-lactamase and spec-
tinomycin testing (Table 2). For azithromycin, 28.6% (4/
14) of countries testing for azithromycin achieved < 90%
concordance between 2007 and 2010. However, 96.0%
(48/50) of these discordant MIC results were within one
Table 1 Poisson regression analysis assessing the relationship between Euro-GASP versus national antimicrobial susceptibility data to
azithromycin, cefixime and ciprofloxaxin by country and overall, 2009 to 2013
Azithromycin Cefixime Ciprofloxacin Source
b
Country IRR P value CI-
lower
CI-
upper
No. of
tests/
years
IRR P value CI-
lower
CI-
upper
No. of
tests/
years
IRR P
value
CI-
lower
CI-
upper
No. of
tests/
years
Austria 0.138 <
0.0001
0.085 0.224 3456/4 0.052 <
0.0001
0.03 0.089 3454/4 1.000 0.995 0.885 1.129 3456/4 1
Belgium 0.68 0.079 0.442 1.046 3198/5 0.065 <
0.0001
0.18 0.241 1919/3 0.973 0.659 0.863 1.098 3198/5 1
Denmark No national azithromycin susceptibility
data available
No national cefixime susceptibility data
available
1.006 0.923 0.895 1.131 2811/5 1
France No national azithromycin susceptibility
data available
0.871 0.747 0.375 2.019 5626/4 0.913 0.251 0.781 1.067 5628/4 2
Germany 6.085 0.083 0.791 46.79 321/1 Model not performed - too few positive
isolates
1.447 0.018 1.064 1.968 321/1 2
Greece 1.078 0.781 0.634 1.832 425/3 1.282 0.415 0.705 2.331 505/3 1.008 0.917 0.87 1.167 1053/5 1
Hungary Model not performed - too few positive
isolates
Model not performed - too few positive
isolates
0.98 0.839 0.803 1.194 776/3 2
Italy 0.944 0.794 0.615 1.451 1144/4 0.863 0.537 0.539 1.38 1170/4 1.003 0.972 0.859 1.171 1134/4 1
Malta No resistant isolates No national cefixime susceptibility data
available
1.004 0.983 0.708 1.424 219/4 1
The
Netherlands
2.23 0.003 1.324 3.757 4440/3 No national cefixime susceptibility data
available
1.097 0.133 0.972 1.237 7695/5 2
Norway 1.389 0.152 0.886 2.177 594/2 2.22 0.037 1.051 4.687 594/2 1.063 0.596 0.848 1.334 594/2 1
Slovakia No national azithromycin susceptibility
data available
0.921 0.883 0.309 2.748 325/1 1.112 0.527 0.801 1.544 325/1 1
Slovenia 1.434 0.287 0.739 2.781 377/5 1.219 0.527 0.66 2.253 377/5 0.987 0.92 0.762 1.277 377/5 1
Sweden 1.818 0.002 1.252 2.638 4158/5 2.005 0.006 1.225 3.281 4158/5 0.956 0.459 0.849 1.077 4158/5 1
The United
Kingdom
0.83 0.554 0.448 1.538 8154/5 1.706 0.042 1.02 2.852 8154/5 1.013 0.825 0.903 1.136 8154/5 1
All countries - univariate
Systema 1.09 0.269 0.935 1.271 26,267 0.863 0.101 0.724 1.029 26,282 1.008 0.697 0.969 1.049 39,889
Sourceb 0.98 0.977 0.227 4.217 26,267 0.248 0.121 0.043 1.443 26,282 0.838 0.209 0.637 1.104 39,889
aSystem = Euro-GASP data (1) vs. national data (2)
bSource = Source of comparison data; all data from Euro-GASP laboratory (1) vs. part or no data from Euro-GASP laboratory (2)
IRR incidence-rate ratio, CI 95% confidence interval. Significant values (< 0.05) in bold
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can easily result in a different susceptibility category,
and these were therefore accepted as comparable results.
In 2012–2013, two laboratories achieved < 90% concord-
ance for azithromycin, however, again all of the discord-
ant MICs were on the resistance breakpoint, so the
results were accepted. For ciprofloxacin, in 2006, one
country had only 49.5% concordance of susceptibility
category, and the laboratory could not explain this large
discrepancy. However, this laboratory showed ciproflox-
acin agreement > 90% for the four subsequent years, so
participation was granted. Two countries achieved only
80% concordance for ciprofloxacin in either 2012 or
2013. However, only a very small number of isolates
were available for comparison from the two laboratories,
so only one to two mismatches resulted in the 80%concordance. The overall concordance of the susceptibil-
ity categories for all antibiotics tested was ≥97% and, ac-
cordingly, participation was granted.
MIC concordance
MIC concordance for cefixime and gentamicin was con-
sistently > 95% (Table 2). Two laboratories had < 95%
ceftriaxone MIC concordance for some of the years ana-
lysed. Thus, one laboratory achieved < 95% concordance
for ceftriaxone MICs in 2006 and 2008 due to technical
problems, which subsequently could be resolved by the
laboratory. The differences were mainly (6/7) just one
MIC doubling dilution more than the accepted two
doubling dilutions. For this particular laboratory, the
data from the subsequent years (2009 and 2010) showed
excellent agreement (99.2 and 100% respectively) so
Fig. 2 Percentage of cefixime resistant isolates in Euro-GASP 2014 and estimates weighted for sexual orientation, gender and age group
(< 25 years and≥ 25 years)
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< 95% ceftriaxone MIC concordance in 2010; however,
this country reported on a very low number of isolates
and only two out of 32 tested isolates were out of the ac-
cepted MIC range. As all other comparison data (100%
agreement in 2010) and EQA data were acceptable, this
laboratory was also accepted for decentralised testing.
Comparison of EQA data
All the Euro-GASP laboratories that requested to par-
ticipate in decentralised testing had < 5% of all MICs
measured for the EQA isolates that were greater than
two MIC doubling dilutions from the modal MIC for
the specific antimicrobial and EQA isolate (Table 3).
The values ranged from 0 to 4.2% and overall 1.6% of
measured MICs differed by more than two doubling di-
lutions from the modal MIC.
Discussion
The overall antimicrobial susceptibility data from the
Euro-GASP laboratories did not significantly differ from
the national/sub-national susceptibility data. The azi-
thromycin and cefixime differences in a small number of
countries were possibly due to isolates with MICs close
to or on the resistance breakpoint, which result in
greater variability in testing and interpretation of the
susceptibility categories. In addition the activity ofazithromycin is sensitive to pH changes in the agar
medium, which can affect MICs and subsequent clinical
interpretation [14]. Some differences between the data-
sets are expected, particularly because Euro-GASP over-
all includes a smaller number of isolates than the
national surveillance, the criteria for selection of isolates
differ, and different susceptibility testing methodologies
can be used. In addition, the national antimicrobial data
are generated from several laboratories in some coun-
tries meaning that the data may be less quality-assured
compared to the Euro-GASP requirements. On the other
hand, national data from a larger number of laboratories
are likely to be more geographically representative. A
limitation of this analysis is the variation in the number
of years for which data were available for comparison:
from one to 5 years depending upon the country. In
addition, the number of tested isolates varied by country
and year and smaller numbers meant wide confidence
intervals for some antimicrobials. Increased availability
of data at the national level would allow for more confi-
dence in analysis and interpretation of these results. In
addition, it is possible that some isolates where included
both in the Euro-GASP and national/regional datasets,
which would lead to dependence between the two data-
sets. This was not accounted for in the analysis since
data were available aggregated to the system/lab level for
the national/sub-national dataset.
Fig. 3 Percentage of ciprofloxacin resistant isolates in Euro-GASP 2014 and estimates weighted for sexual orientation, gender and age group
(< 25 years and≥ 25 years)
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antimicrobial resistance data and the weighted resistance
data in respect to the available patient characteristic data
from the epidemiological surveillance [9]. In general,
weighting of the Euro-GASP data did not provide signifi-
cantly different estimates of resistance levels that would
impact on the 5% threshold used to assess the continuedTable 2 Percentage concordance of Euro-GASP centralised testing a
Year Ceftriaxone Azithromycin Cefixime Cipr
2006 87.6–100 95.3–100 – 49.5
2007 95.3–100 75.6–100 – 90.3
2008 93.8–100 41.7–100 – 94.2
2009 95.8–100 87–100 100 92.9
2010 93.8–100 89.1–100 97.1–100 92.6
2012 95.8–100 75a – 100 95.8–100 80b
2013 95.4–100 89a - 100 95.5–100 80b
The table contains data from; Austria (2012–2013, all antimicrobials); Belgium (2006
gentamicin or β-lactamase data); Denmark (2006–2009, ceftriaxone, ciprofloxacin an
data); Greece (2007–2010, no gentamicin data); Iceland (2012–2013, no spectinomy
and cefixime data only); Italy (2007, azithromycin and ciprofloxacin only, 2010–2011
Norway (2012–2013, no β-lactamase data); Portugal (2009–2010, no azithromycin d
gentamicin data); Sweden (2006–2009, no cefixime or gentamicin data); The Nether
the UK (2006–2010, no gentamicin data). Data from Slovenia was only available for
specified limits
aAll discrepant isolates on the resistance breakpoint
bOnly a very low number of isolates available for comparison from two labs, so 1–2
of the resistance category comparisons was ≥97%clinical utility of first-line antimicrobials in the empirical
treatment of gonorrhoea. However, one limitation of this
analysis is the variations in reporting, such as sentinel
epidemiological surveillance for gonorrhoea in some
countries [12], which means the data used for weighting
are not necessarily the true population of gonorrhoea
patients or the same population Euro-GASP isolatesnd laboratories’ own antimicrobial susceptibility testing results
ofloxacin Spectinomycin Gentamicin β-lactamase
–99.1 – – 96.3–100
–100 – – 100
–100 100 – 98–100
–100 100 100 97.5–100
–100 100 100 98.2–100
- 100 100 98.1–100 97.9–98.1
- 100 100 97.3–100 99.1–100
–2009, no gentamicin or cefixime data); Cyprus (2012–2013, no spectinomycin,
d β-lactamase data only); France (2008–2010, no azithromycin or gentamicin
cin, gentamicin or β-lactamase data); Ireland (2012, ceftriaxone, azithromycin
all antimicrobials); Malta (2012–2013, no gentamicin or β-lactamase data);
ata); Slovenia (2011–2013, all antimicrobials); Spain (2006–2009, no cefixime or
lands (2006–2010, ceftriaxone, ciprofloxacin and β-lactamase data only) and
2011 so data is not shown, however all concordances for 2011 were within
mismatches resulted in only 80% concordance, however overall concordance
Table 3 Concordance in external quality assessment (EQA; MIC and β-lactamase testing results only)
Country No. of susceptibility tests % of isolates with MICs >2 doubling dilutions from the modal MIC (no.)
Austria 210 1.4 (3)
Belgium 500 0
Cyprusa 24 0
Denmark 420 0.5 (2)
France 460 2.6 (12)
Greece 291 0.3 (1)
Icelandb 40 0
Irelandc 30 0
Italy 430 4.2 (18)
Malta 230 1.3 (3)
Norway 180 0.6 (1)
Portugal 430 2.1 (9)
Slovenia 730 0.6 (4)
Spain 520 2.5 (13)
Sweden 490 1.4 (7)
The Netherlands 210 0
United Kingdom 510 3.1 (16)
aLow number of isolates available and previously used disc diffusion method
bRecent Euro-GASP member and very low number of isolates available
cPreviously used disc diffusion method for EQA and therefore low number of EQA MIC results available
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some patient data in the epidemiological surveillance
and/or the Euro-GASP dataset. This was particularly a
problem for the epidemiological variable sexual orienta-
tion, which was not reported by eight countries and this
also means that combined weighting using all three vari-
ables (age, gender and sexual orientation) was not pos-
sible due to the low data completeness. Consequently,
ensuring and comprehensively assessing a truly repre-
sentative sample will not be possible until country
reporting is improved, which is an ongoing activity. Fur-
thermore, the heterogeneity of the epidemiological sur-
veillance, as previously discussed [8], is a weakness in
this analysis, and in the absence of complete compre-
hensive epidemiological surveillance in all countries,
weighting of the Euro-GASP data might not be of any
significant value, even with a complete Euro-GASP
dataset.
Only a few previous studies have investigated the rep-
resentativeness of national or international GASPs.
Comparisons of the distribution of patient epidemio-
logical data in both the Euro-GASP and the ECDC epi-
demiological surveillance data were investigated
previously [8] and showed that the distribution of the re-
ported patient characteristics of age and sexual orienta-
tion between the two surveillance systems significantly
differed, except for the proportion of MSM, and that
male heterosexuals were over-represented in the Euro-
GASP data set. However the weighted analysis in thecurrent study investigated data from individual countries
which submitted both patient data linked to the gono-
coccal isolates, and to the epidemiological surveillance,
and these showed high concordance. A study from the
Gonococcal Resistance to Antimicrobials Surveillance
Programme (GRASP) in England and Wales also used
weighting to estimate resistance prevalence [10]. Their
investigations revealed that the GRASP sample, which is
also based on annual 3-monthly sentinel surveillance,
provides reliable estimates of resistance levels and
weighted estimates would not have changed national
recommendations to change treatment guidelines. Ac-
cordingly, the findings of the present study evaluating
Euro-GASP are in full concordance with the findings of
the national GRASP study. Another British study [15]
investigated two sampling methods over 3 months; every
5th isolate compared with the first 20 each month. Ana-
lysis of the susceptibility profiles of the gonococcal iso-
lates revealed no significant difference between the two
sampling methods. The authors concluded that major
changes can be monitored in the gonococcal population
using a small sample of the population. This is in con-
cordance with our results where the Euro-GASP data,
with an average of 100 isolates per country/year, and the
national data frequently compiled using much larger
samples were mainly highly concordant. Two studies
have evaluated the number of isolates tested in a gono-
coccal antimicrobial susceptibility survey compared to
the number of reported gonorrhoea cases and both have
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(NAATs) for detection of N. gonorrhoeae, as opposed to
culture, had an impact on representativeness [16, 17]. In
Euro-GASP 2015, the overall number of isolates tested
was 3% of the total number of cases reported via the epi-
demiological surveillance for the same countries [18].
The main reasons for this are the lack of widely available
culture possibilities in several countries and the broad
implementation of gonococcal NAATs. For comparison,
in the US Gonococcal Isolate Surveillance Project
(GISP), isolates from approximately 1.5% of the reported
gonorrhoea cases are tested for antimicrobial susceptibil-
ity and only isolates from urethral samples from males
are included [19]. In Euro-GASP, isolates are collected
from both males and females, and from all anatomical
sites of infection. For some countries with low numbers
of gonorrhoea cases, the numbers of isolates submitted
to Euro-GASP are similar to the overall number of re-
ported gonorrhoea cases, whereas the numbers of iso-
lates are capped for the other Euro-GASP countries for
practical and resource reasons.
The advantages of decentralised testing within Euro-
GASP include decreased cost, enhanced sustainability,
improved timeliness, increased efficiency, and encour-
agement of more laboratories to test more isolates in a
quality-assured manner and focus on most appropriate
antimicrobials used in treatment. The antimicrobial sus-
ceptibility data submitted from the decentralised Euro-
GASP laboratories were also overall highly concordant
with the data generated by the Euro-GASP centralised
testing. This, along with appropriate EQA data, supports
the continuation of Euro-GASP laboratories’ participat-
ing in decentralised testing, even when slightly different
methodologies are used. Likely reasons for the few iden-
tified discrepancies include differences in agar media,
size of inoculum, incubation (atmosphere, temperature
and time), as well as the subjective reading and inter-
pretation of the antimicrobial susceptibility testing. To
ensure continual confidence in the quality of the decen-
tralised data, all decentralised laboratories are requested
to use the same quality control strain panel [18] and
continue to participate in the EQA [20]. Any problems
identified in the EQA are promptly investigated further.
Potential problems with decentralised testing include
less control over the surveillance process, e.g. delays in
submitting data from countries that delays publication
of the results, and that laboratories may change to differ-
ent methods or stop their own susceptibility testing par-
ticularly if resources locally are reduced. Work is
ongoing to switch those countries that currently rely on
centralised testing to the decentralised model through
training and country visits.
The added value of Euro-GASP, as opposed to relying
upon just the national reports, includes the generation ofregional data and standardised reporting via TESSy, in-
cluding a drive for improved patient data reporting so ap-
propriate risk analysis can be performed. The overall
quality of the network is enhanced by methodological
standardisation, participation in the EQA and delivery of
training. Euro-GASP is performed annually as opposed to,
at times, episodic analysis from some countries. Not all
countries produce annual reports but rely upon publica-
tions which describe the antimicrobial resistance (AMR)
situation over a number of combined years, and many
have limited epidemiological analysis. Euro-GASP is a col-
laborative network that can share ideas and expertise, and
allows a platform to highlight emerging issues as well as
perform additional projects and surveys [21–23].
As antimicrobial resistance in N. gonorrhoeae is now a
global problem, a reliable global picture is required. Inter-
national gonococcal antimicrobial susceptibility surveil-
lance is a goal of the WHO and is co-ordinated by the
WHO Global GASP [24]. Dillon [25] has described the
difficulties faced with international surveillance, such as
representativeness, timely reporting of data, ability to pub-
lish data, lack of available cultures, funding, and substan-
tial differences between regional surveillance programmes.
When comparing international antimicrobial susceptibility
data, it is important that the same breakpoints are used,
and even though this is no longer an issue for the EU/EEA
where the breakpoints have been harmonised [11], vari-
ation in interpretive criteria still confounds comparisons
with other regions. An internationally agreed methodology
and harmonised breakpoints would be very useful to com-
pare gonococcal AMR data from around the world, as
would the use of identical WHO reference strains [26].
The main challenge for any GASP is that NAATs are rap-
idly replacing culture for detection of N. gonorrhoeae
internationally. Although antimicrobial resistance deter-
minants detected by PCRs or sequencing will most likely
be informing antimicrobial resistance surveillance pro-
grammes more frequently in the future, molecular predic-
tion of antimicrobial resistance in N. gonorrhoeae
currently has important inherent limitations, including
that new or unknown resistance determinants are not de-
tected, and the suboptimal correlates between molecular
resistance determinants and MICs of several antimicro-
bials [27]. Accordingly, phenotypic antimicrobial suscepti-
bility surveillance, in the future supplemented with
molecular resistance prediction, will remain the basis for
informing revisions of treatment guidelines and it is very
important to maintain and strengthen capacity to perform
gonococcal culture and antimicrobial susceptibility testing
globally.
Conclusions
The key functions of Euro-GASP are to detect emerging
and developing antimicrobial resistance, establish trends
Cole et al. BMC Infectious Diseases         (2019) 19:1040 Page 11 of 12of antimicrobial resistance over time, and inform refine-
ments of treatment guidelines. This study shows that the
prevalence of antimicrobial resistance reported by the
Euro-GASP sentinel surveillance system appropriately
reflects the antimicrobial resistance situation in the EU/
EEA, and Euro-GASP can therefore provide robust re-
sistance estimates to inform the European guideline for
the diagnosis and treatment of gonorrhoea [4].
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